Key facts
- This page summarizes Thilo Schroeder's Form 4 filing for PMV Pharmaceuticals, Inc. (PMVP).
- 1 reported transaction and 0 derivative rows are listed below.
- Accepted by SEC: 08 Oct 2021, 17:57.
Thilo Schroeder - 06 Oct 2021 Form 4 Insider Report for PMV Pharmaceuticals, Inc. (PMVP)
- Reporting relationship
- Director
- Issuer ticker
- PMVP
- Reported as of
- 06 Oct 2021
- Net transaction value
- -$24,120
- SEC form
- 4
- Accepted by SEC
- 08 Oct 2021, 17:57:47 UTC
- Prior SEC filing
- 04 Oct 2021
- Next SEC filing
- 09 Mar 2022
- Source filing
- View source filing
- Reporting owner signature
- /s/ Darren DeStefano, Attorney-in-Fact
Source evidence
Original filing metadata and source links for verification.
5 source fields
Reporting owner
1 detail
Key filing fact
Thilo Schroeder filed Form 4 for PMV Pharmaceuticals, Inc. (PMVP) on 08 Oct 2021.
Change
- Previous filing in this sequence was filed on 04 Oct 2021.
- Current net transaction value: -$24,120.
Research use
- This tells you what this filing adds before you inspect full transaction and derivative tables.
- You can trace every row back to the original SEC filing document.
Evidence
Filed on Form 4
View source filing
Ownership activity is grounded in SEC Form 4 disclosures.
Reported non-derivative transactions
Shares, units, or other non-derivative securities reported in this filing.
PMVP
transaction
Common Stock
Sale
- Transaction value
- $24,120
- Shares
- -800
- Change %
- -0.07%
- Price
- $30.15
- Shares after
- 1,101,283
- Date
- 06 Oct 2021
- Ownership
- See footnote
- Footnotes
- F1, F2, F3
* marks a reported price that did not pass the local price check.
Additional SEC filing notes
Filing notes and footnotes
Explanation of responses 3 footnotes
Footnote F1
Shares were sold pursuant to a Rule 10b5-1 trading plan.
Footnote F2
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $30.03 to $30.25 inclusive. The Reporting Person undertakes to provide to the Issuer, any security holder of the Issuer, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.
Footnote F3
The shares are held of record by Nextech V Oncology S.C.S., SICAV-SIF. The Reporting Person is a partner at Nextech Invest AG and in the Investment Committee of Nextech Invest AG, with significant influence over Nextech V Oncology S.C.S., SICAV-SIF in terms of investment decisions, selling strategy of shares and voting power and as a result, may be deemed to have beneficial ownership over such securities. The Reporting Person disclaims beneficial ownership over the shares reported herein except to the extent of his pecuniary interest therein, if any.